14 September 2021 - Sacituzumab govitecan is a new treatment option for adult patients with unresectable locally advanced or metastatic triple negative breast cancer.

The TGA has approved Sacituzumab govitecan (Trodelvy) for the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer who have received at least two prior systemic therapies, including at least one prior therapy for locally advanced or metastatic disease.

Read Australian prescription medicine decision summary for Trodelvy